Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

NEDDylation maintains oocyte quality by stabilizing mitochondrial transcription.

Science advances·2026

Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026

Same author

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.

bioRxiv : the preprint server for biology·2026

Same author

Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress.

Science advances·2026

Same author

Enhancing Pathology Knowledge for Biomedical Scientists: Pilot Cohort Study of a Comprehensive Self-Paced Tutorial for Bridging Fundamental Concepts With Translational Applications.

JMIR medical education·2026

Same author

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment.

Cancer immunology research·2026

Same journal

Fueling Immunotherapy Resistance: SSBP4 Links Tumor Cholesterol Biosynthesis to Immune Evasion.

Cancer immunology research·2026

Same journal

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

Cancer immunology research·2026

Same journal

Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy.

Cancer immunology research·2026

Same journal

ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy.

Cancer immunology research·2026

Same journal

DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies.

Cancer immunology research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer.

Emily Bontekoe¹, Minying Zhang¹, Peixin Jiang¹

¹Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Immunology Research

|March 19, 2026

Summary

This summary is machine-generated.

This study shows that the FOXM1 protein is immunogenic and can be targeted in cancer. T cell receptor (TCR) engineered T cells targeting FOXM1 effectively reduced tumor growth and improved survival in preclinical models.

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Mar 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

FOXM1 is a transcription factor highly expressed in many cancers, driving tumor progression.
Targeting cancer-specific antigens with immunotherapy is a promising approach.

Purpose of the Study:

To evaluate the immunogenicity of FOXM1.
To investigate the feasibility of targeting FOXM1 using T cell receptor (TCR) engineering for cancer therapy.

Main Methods:

Identification of FOXM1-derived epitopes presented on HLA-A*02:01, HLA-A*24:02, and HLA-A*23:01.
Generation and validation of TCR-engineered T cells (TCR-T cells) for specificity and sensitivity.
Assessment of anti-tumor efficacy via adoptive transfer of TCR-T cells in a murine tumor model.

Main Results:

FOXM1-derived epitopes were identified as immunogenic, triggering T cell activation and cytotoxic responses.
TCR-T cells demonstrated specificity and sensitivity against FOXM1 epitopes.
Adoptive transfer of TCR-T cells significantly reduced tumor growth and prolonged survival in vivo.

Conclusions:

FOXM1 is immunogenic and represents a viable target for TCR-based immunotherapy.
TCR engineering targeting FOXM1 shows significant anti-tumor potential in preclinical settings.